PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30858427-11	2019	Consistent with a key role for PFKFB3 is the finding that the PFKFB3 inhibitor, 3PO, attenuated the LPS + Abeta-induced glycolysis.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	80-83	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	31-37
32620030-2	2020	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) is frequently used as a glycolysis inhibitor and is thought to inhibit PFKFB3.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-46	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	124-130
32620030-2	2020	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) is frequently used as a glycolysis inhibitor and is thought to inhibit PFKFB3.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	48-51	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	124-130
32620030-4	2020	To demonstrate binding of 3PO to PFKFB3, we used isothermal titration calorimetry.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	26-29	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	33-39
32051533-7	2020	In addition, PFKFB3 expression and aerobic glycolysis were also detected in the mouse model of LPS-induced pulmonary fibrosis, which could be reversed by the intraperitoneal injection of PFKFB3 inhibitor 3PO.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	204-207	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	13-19
32051533-7	2020	In addition, PFKFB3 expression and aerobic glycolysis were also detected in the mouse model of LPS-induced pulmonary fibrosis, which could be reversed by the intraperitoneal injection of PFKFB3 inhibitor 3PO.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	204-207	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	187-193
32188275-4	2020	Approach and Results: ApoE-/- (apolipoprotein E deficient) mice treated with 3PO (50 microg/g, ip; 4x/wk, 4 weeks) showed a metabolic switch toward ketone body formation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	77-80	apolipoprotein E	Mus musculus	22-26
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	56-65
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	67-89
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	tumor necrosis factor	Mus musculus	115-124
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	tumor necrosis factor	Mus musculus	126-153
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	vascular cell adhesion molecule 1	Mus musculus	164-170
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	vascular cell adhesion molecule 1	Mus musculus	172-205
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	intercellular adhesion molecule 1	Mus musculus	211-217
32188275-9	2020	Moreover, 3PO induced autophagy, which in turn impaired NF-kappaB (nuclear factor-kappa B) signaling and inhibited TNF-alpha (tumor necrosis factor-alpha)-mediated VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1) upregulation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	10-13	intercellular adhesion molecule 1	Mus musculus	219-252
30776389-6	2019	The potent antagonist 3-(3pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) was used to block PFKFB3 activity in vivo (50 mg/kg, i.p.)	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	22-67	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	92-98
30776389-9	2019	3PO also suppressed the LPS-induced secretion of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and lactate in the serum, in addition to lactate in the myocardium.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	tumor necrosis factor	Mus musculus	49-76
30776389-9	2019	3PO also suppressed the LPS-induced secretion of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and lactate in the serum, in addition to lactate in the myocardium.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	interleukin 1 alpha	Mus musculus	78-100
30776389-9	2019	3PO also suppressed the LPS-induced secretion of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and lactate in the serum, in addition to lactate in the myocardium.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	interleukin 6	Mus musculus	102-106
32366406-0	2020	3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	32-85
32366406-2	2020	The aim of the study was to examine the effect of the (2E)-3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), as an inhibitor of PFKFB3, on human melanoma cells (A375) with endogenous BRAFV600E mutation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	54-105	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	132-138
32130250-1	2020	Inhibition of the key glycolytic activator 6-phosphofructokinase 2/fructose-2,6-bisphosphatase-3 (PFKFB3) by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) strongly attenuates pathological angiogenesis in cancer and inflammation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	109-155	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	43-96
32130250-1	2020	Inhibition of the key glycolytic activator 6-phosphofructokinase 2/fructose-2,6-bisphosphatase-3 (PFKFB3) by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) strongly attenuates pathological angiogenesis in cancer and inflammation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	109-155	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	98-104
32130250-4	2020	We found that 3PO caused a rapid and transient reduction in IL-1beta- and TNF-induced phosphorylation of both IKKalpha/beta and JNK, thus inhibiting signaling through the NFkappaB and the stress-activated kinase pathways.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	14-17	interleukin 1 alpha	Homo sapiens	60-68
32130250-4	2020	We found that 3PO caused a rapid and transient reduction in IL-1beta- and TNF-induced phosphorylation of both IKKalpha/beta and JNK, thus inhibiting signaling through the NFkappaB and the stress-activated kinase pathways.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	14-17	tumor necrosis factor	Homo sapiens	74-77
32130250-4	2020	We found that 3PO caused a rapid and transient reduction in IL-1beta- and TNF-induced phosphorylation of both IKKalpha/beta and JNK, thus inhibiting signaling through the NFkappaB and the stress-activated kinase pathways.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	14-17	mitogen-activated protein kinase 8	Homo sapiens	110-131
32130250-4	2020	We found that 3PO caused a rapid and transient reduction in IL-1beta- and TNF-induced phosphorylation of both IKKalpha/beta and JNK, thus inhibiting signaling through the NFkappaB and the stress-activated kinase pathways.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	14-17	nuclear factor kappa B subunit 1	Homo sapiens	171-179
31213542-3	2019	Heterozygous global deficiency of Pfkfb3 protected mice from developing hypoxia-induced PH, and administration of the PFKFB3 inhibitor 3PO almost completely prevented PH in rats treated with Sugen 5416/hypoxia, indicating a causative role of PFKFB3 in the development of PH.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	135-138	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	118-124
31213542-3	2019	Heterozygous global deficiency of Pfkfb3 protected mice from developing hypoxia-induced PH, and administration of the PFKFB3 inhibitor 3PO almost completely prevented PH in rats treated with Sugen 5416/hypoxia, indicating a causative role of PFKFB3 in the development of PH.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	135-138	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Rattus norvegicus	242-248
30858427-11	2019	Consistent with a key role for PFKFB3 is the finding that the PFKFB3 inhibitor, 3PO, attenuated the LPS + Abeta-induced glycolysis.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	80-83	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	62-68
30858427-11	2019	Consistent with a key role for PFKFB3 is the finding that the PFKFB3 inhibitor, 3PO, attenuated the LPS + Abeta-induced glycolysis.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	80-83	amyloid beta (A4) precursor protein	Mus musculus	106-111
29866066-10	2018	In combination with either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in both platinum sensitive and platinum resistant ovarian cancer cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	52-55	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	65-71
27069123-2	2016	Previous studies have indicated that proliferation of cancer cells can be inhibited by treatment with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB) namely 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	208-254	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	138-192
28235572-8	2017	Treatment of ConA-stimulated thymocytes with PFK-2 inhibitor (3PO) or MK-2206 led to significant decreases in Fru-2,6-P2 content, medium lactate accumulation and rates of cell proliferation and protein synthesis.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	62-65	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	45-50
28235572-8	2017	Treatment of ConA-stimulated thymocytes with PFK-2 inhibitor (3PO) or MK-2206 led to significant decreases in Fru-2,6-P2 content, medium lactate accumulation and rates of cell proliferation and protein synthesis.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	62-65	zinc finger and BTB domain containing 22	Homo sapiens	110-113
28348059-6	2017	Experiments with the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one showed that PFKFB3 activity was required for estrogen-mediated HUVEC migration via GPER1.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	38-84	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	21-27
28348059-6	2017	Experiments with the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one showed that PFKFB3 activity was required for estrogen-mediated HUVEC migration via GPER1.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	38-84	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	97-103
28348059-6	2017	Experiments with the PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one showed that PFKFB3 activity was required for estrogen-mediated HUVEC migration via GPER1.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	38-84	G protein-coupled estrogen receptor 1	Homo sapiens	168-173
27069123-2	2016	Previous studies have indicated that proliferation of cancer cells can be inhibited by treatment with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB) namely 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	208-254	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	194-199
27069123-2	2016	Previous studies have indicated that proliferation of cancer cells can be inhibited by treatment with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB) namely 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	256-259	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	138-192
27069123-2	2016	Previous studies have indicated that proliferation of cancer cells can be inhibited by treatment with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB) namely 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO).	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	256-259	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	194-199
26284610-10	2015	Inhibition of glycolysis by 3PO demonstrates therapeutic benefit in bleomycin-induced and transforming growth factor-beta1-induced lung fibrosis in mice.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	28-31	transforming growth factor, beta 1	Mus musculus	90-122
24451478-2	2014	One family member, PFKFB3, has been shown to be highly expressed and activated in human cancer cells, and derivatives of a PFKFB3 inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), are currently being developed in clinical trials.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	141-187	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	19-25
24451478-2	2014	One family member, PFKFB3, has been shown to be highly expressed and activated in human cancer cells, and derivatives of a PFKFB3 inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), are currently being developed in clinical trials.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	141-187	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	123-129
24451478-8	2014	We speculated that the induction of autophagy might protect cells from the pro-apoptotic effects of 3PO and found that agents that disrupt autophagy, including chloroquine, increased 3PO-induced apoptosis as measured by double staining with Annexin V and propidium iodide in both HCT-116 cells and Lewis lung carcinoma (LLC) cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	183-186	annexin A5	Homo sapiens	241-250
24332967-3	2014	Here, we show that blockade of PFKFB3 by the small molecule 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) reduced vessel sprouting in endothelial cell (EC) spheroids, zebrafish embryos, and the postnatal mouse retina by inhibiting EC proliferation and migration.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	60-106	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Danio rerio	31-37
23674815-3	2013	Previously, a weak competitive inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was found to reduce the glucose metabolism and proliferation of cancer cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	52-98	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	44-50
35354250-10	2022	3PO repaired the damaged BM EPCs by reducing FOXO3A expression and phospho-NF-kappaB p65 in patients after chemotherapy.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	forkhead box O3	Homo sapiens	45-51
35354250-10	2022	3PO repaired the damaged BM EPCs by reducing FOXO3A expression and phospho-NF-kappaB p65 in patients after chemotherapy.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	75-88
35155224-7	2022	3PO, a PFKFB3 inhibitor, reduced lactate level and sensitized A2780CP cells to cisplatin treatment, along with the modulation of inhibitors of apoptosis proteins (c-IAP1, c-IAP2 and survivin) and an immune modulator CD70.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	7-13
35155224-7	2022	3PO, a PFKFB3 inhibitor, reduced lactate level and sensitized A2780CP cells to cisplatin treatment, along with the modulation of inhibitors of apoptosis proteins (c-IAP1, c-IAP2 and survivin) and an immune modulator CD70.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	baculoviral IAP repeat containing 2	Homo sapiens	163-169
35155224-7	2022	3PO, a PFKFB3 inhibitor, reduced lactate level and sensitized A2780CP cells to cisplatin treatment, along with the modulation of inhibitors of apoptosis proteins (c-IAP1, c-IAP2 and survivin) and an immune modulator CD70.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	baculoviral IAP repeat containing 3	Homo sapiens	171-177
35155224-7	2022	3PO, a PFKFB3 inhibitor, reduced lactate level and sensitized A2780CP cells to cisplatin treatment, along with the modulation of inhibitors of apoptosis proteins (c-IAP1, c-IAP2 and survivin) and an immune modulator CD70.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	CD70 molecule	Homo sapiens	216-220
22591674-4	2012	A small molecule antagonist of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), recently has been shown to reduce F2,6BP synthesis, glucose uptake and proliferation in transformed cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	39-85	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	31-37
22591674-10	2012	We then found that exposure to the PFKFB3 small molecule antagonist, 3PO (1-10 muM), markedly attenuated the stimulation of F2,6BP synthesis, 2-[1-14C]-deoxy-D-glucose uptake, lactate secretion, TNF-alpha secretion and T cell aggregation and proliferation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	69-72	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Mus musculus	35-41
22591674-10	2012	We then found that exposure to the PFKFB3 small molecule antagonist, 3PO (1-10 muM), markedly attenuated the stimulation of F2,6BP synthesis, 2-[1-14C]-deoxy-D-glucose uptake, lactate secretion, TNF-alpha secretion and T cell aggregation and proliferation.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	69-72	tumor necrosis factor	Mus musculus	195-204
18202014-3	2008	We report herein the computational identification of a small-molecule inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), which suppresses glycolytic flux and is cytostatic to neoplastic cells.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	91-137	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	83-89
18202014-4	2008	3PO inhibits recombinant PFKFB3 activity, suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	25-31